ARQT News and Press, Arcutis Biotherapeutics Inc. From 05/13/23

2023-05-13 19:53:08 ET Arcutis Biotherapeutics, Inc. (ARQT) Q1 2023 Results Conference Call May 09, 2023 04:30 PM ET Company Participants Eric McIntyre - Head of Investor Relations Frank Watanabe - President & Chief Executive Officer Patrick Burnett - Chief M...

2023-05-09 17:09:03 ET Arcutis Biotherapeutics press release ( NASDAQ: ARQT ): Q1 GAAP EPS of -$1.31. Revenue of $2.8M. For further details see: Arcutis Biotherapeutics reports Q1 results

Achieved net revenues of $2.8 million for ZORYVE® (roflumilast) cream 0.3% in the first quarter of 2023, with unit demand growth nearly doubling quarter-over-quarter Continued expansion of commercial payer coverage for ZORYVE in plaque psoriasis with over 110 million commercial lives cov...

A total of 652 children, ages 2 to 5, were enrolled in the study Topline data expected in the third quarter Atopic dermatitis (AD) affects approximately 26 million adults and children in the United States WESTLAKE VILLAGE, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Arcutis Bio...

First novel steroid-free topical with a new mechanism of action approved for plaque psoriasis in over 25 years First ZORYVE approval outside of the U.S. marks key milestone for Arcutis WESTLAKE VILLAGE, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, In...

WESTLAKE VILLAGE, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a conference call and webcas...

2023-04-24 08:58:15 ET Summary Arcutis Biotherapeutics' PDUFA date of December 16, 2023 established for potential FDA approval of Roflumilast for the treatment of patients with seborrheic dermatitis. NDA filing of ZORYVE for the treatment of patients with atopic dermatitis expecte...

2023-04-18 08:54:20 ET The U.S. Food and Drug Administration (FDA) has accepted for review Arcutis Biotherapeutics' ( NASDAQ: ARQT ) application seeking approval for roflumilast foam 0.3% to treat  seborrheic dermatitis in patients nine years of age and older. S...

FDA has set a target action date of December 16, 2023 NDA supported by positive efficacy and safety data from the Phase 2 and pivotal Phase 3 trials of roflumilast foam If approved, roflumilast foam would be the first topical drug for seborrheic dermatitis with a new mechanism of action...

2023-04-05 11:05:28 ET Arcutis Biotherapeutics ( NASDAQ: ARQT ) said its plaque psoriasis cream Zoryve is being covered without prior authorizations by an additional eight national and regional health plans, effective April 1. The company noted that, combined with the pre...